The medical technology company Synthetic MR provides financial guidance ahead of the upcoming rights issue. This is stated in a press release. Net sales for the fourth quarter of 2025 preliminarily amounted to SEK 18.0 million (12.6), corresponding to growth of 43 percent. Net sales for the full year 2025 preliminarily amounted to SEK 57.0 million (55.7), corresponding to an increase of 2 percent.The operating result, ebit, for the fourth quarter of 2025 preliminarily amounted to SEK -5.3 million (-7.5), while the operating result for the full year 2025 amounted to SEK -49.3 million (-18.3). The preliminary adjusted operating result for the full year 2025, after an impairment of operating items of SEK -18.5 million and acquisition costs of SEK -0.3 million that are reported as an item affecting comparability, amounts to SEK -30.5 million. Most of the impairment relates to contract assets.The company’s cash and cash equivalents at year-end preliminarily amounted to SEK 7.4 million. One year earlier, cash and cash equivalents were SEK 51.1 million, of which SEK 40 million pertained to a short-term loan received to enable the acquisition of Combinostics. The loan was repaid with the proceeds from the rights issue during 2024/2025.The year-end report will be published on February 6, 2026. The share traded ex-rights in the rights issue on January 15. The subscription period runs from January 20 to February 3. The terms are 1:2, meaning that two existing shares entitle the holder to subscribe for one new share at a subscription price of SEK 1.10 per share